Related references
Note: Only part of the references are listed.Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Multicenter Study of Anidulafungin and Micafungin MIC Distributions and Epidemiological Cutoff Values for Eight Candida Species and the CLSI M27-A3 Broth Microdilution Method
M. A. Pfaller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Positions and Numbers of FKS Mutations in Candida albicans Selectively Influence In Vitro and In Vivo Susceptibilities to Echinocandin Treatment
M. Lackner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Real-World Experience with Echinocandin MICs against Candida Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates
Gregory A. Eschenauer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of Micafungin
Fernando Cesar Bizerra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Role of FKS Mutations in Candida glabrata: MIC Values, Echinocandin Resistance, and Multidrug Resistance
Cau D. Pham et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Nicholas D. Beyda et al.
CLINICAL INFECTIOUS DISEASES (2014)
Systemic Antifungal Prophylaxis After Hematopoietic Stem Cell Transplantation: A Meta-Analysis
Panayiotis D. Ziakas et al.
CLINICAL THERAPEUTICS (2014)
Echinocandin resistance: an emerging clinical problem?
Maiken C. Arendrup et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2014)
Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?
A. Fekkar et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2014)
Candida glabrata Intra-Abdominal Candidiasis Is Characterized by Persistence within the Peritoneal Cavity and Abscesses
Shaoji Cheng et al.
INFECTION AND IMMUNITY (2014)
Transcriptional Activation of Heat Shock Protein 90 Mediated Via a Proximal Promoter Region as Trigger of Caspofungin Resistance in Aspergillus fumigatus
Frederic Lamoth et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Development of echinocandin-resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy
M. A. Ruggero et al.
TRANSPLANT INFECTIOUS DISEASE (2014)
A Tetraploid Intermediate Precedes Aneuploid Formation in Yeasts Exposed to Fluconazole
Benjamin D. Harrison et al.
PLOS BIOLOGY (2014)
Drug-Resistant Candida glabrata Infection in Cancer Patients
Dimitrios Farmakiotis et al.
EMERGING INFECTIOUS DISEASES (2014)
Stepwise Development of a Homozygous S80P Substitution in Fks1p, Conferring Echinocandin Resistance in Candida tropicalis
Rasmus Hare Jensen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Elevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin
Louise A. Walker et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Role of Matrix β-1,3 Glucan in Antifungal Resistance of Non-albicans Candida Biofilms
K. F. Mitchell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Species-Specific and Drug-Specific Differences in Susceptibility of Candida Biofilms to Echinocandins: Characterization of Less Common Bloodstream Isolates
Maria Simitsopoulou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Rapid Emergence of Echinocandin Resistance in Candida glabrata Resulting in Clinical and Microbiologic Failure
James S. Lewis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Rapid Emergence of Echinocandin Resistance during Candida kefyr Fungemia Treatment with Caspofungin
A. Fekkar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
Barbara D. Alexander et al.
CLINICAL INFECTIOUS DISEASES (2013)
Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.
Maiken C. Arendrup et al.
DRUG RESISTANCE UPDATES (2013)
A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade
A. M. Tortorano et al.
INFECTION (2013)
Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance
Michael A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
Newer Antifungal Agents for Fungal Infection Prevention During Hematopoietic Cell Transplantation: A Meta-Analysis
S. -X. Xu et al.
TRANSPLANTATION PROCEEDINGS (2013)
Regulatory Role of Glycerol in Candida albicans Biofilm Formation
Jigar V. Desai et al.
MBIO (2013)
Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo
Keunsook K. Lee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Fks1 and Fks2 Are Functionally Redundant but Differentially Regulated in Candida glabrata: Implications for Echinocandin Resistance
Santosh K. Katiyar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis
Michaela Doering et al.
BMC INFECTIOUS DISEASES (2012)
Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011
Angela Ahlquist Cleveland et al.
CLINICAL INFECTIOUS DISEASES (2012)
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.
W. W. Hope et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Micafungin A Review of its Use in the Prophylaxis and Treatment of Invasive Candida Infections
Lesley J. Scott
DRUGS (2012)
Topological and Mutational Analysis of Saccharomyces cerevisiae Fks1
Michael E. Johnson et al.
EUKARYOTIC CELL (2012)
Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction
Kelley R. Healey et al.
MOLECULAR MICROBIOLOGY (2012)
The Hsp90 Co-Chaperone Sgt1 Governs Candida albicans Morphogenesis and Drug Resistance
Rebecca S. Shapiro et al.
PLOS ONE (2012)
Hidden Killers: Human Fungal Infections
Gordon D. Brown et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Sheena D. Singh-Babak et al.
PLOS PATHOGENS (2012)
Candida spp. with Acquired Echinocandin Resistance, France, 2004-2010
Eric Dannaoui et al.
EMERGING INFECTIOUS DISEASES (2012)
Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients
Olivier Lortholary et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Prior Caspofungin Exposure in Patients with Hematological Malignancies Is a Risk Factor for Subsequent Fungemia Due to Decreased Susceptibility in Candida spp.: a Case-Control Study in Paris, France
Elodie Blanchard et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Candida glabrata Mutants Demonstrating Paradoxical Reduced Caspofungin Susceptibility but Increased Micafungin Susceptibility
Kelley R. Healey et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
Nathan P. Wiederhold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin
J. L. Slater et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
New Fks Hot Spot for Acquired Echinocandin Resistance in Saccharomyces cerevisiae and Its Contribution to Intrinsic Resistance of Scedosporium Species
Michael E. Johnson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009)
Michael A. Pfaller et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
M. A. Pfaller et al.
DRUG RESISTANCE UPDATES (2011)
Echinocandin Antifungal Drugs in Fungal Infections A Comparison
Sharon C. -A. Chen et al.
DRUGS (2011)
Current perspectives on echinocandin class drugs
David S. Perlin
FUTURE MICROBIOLOGY (2011)
Regulation of Cell Wall Biogenesis in Saccharomyces cerevisiae: The Cell Wall Integrity Signaling Pathway
David E. Levin
GENETICS (2011)
Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)
Michael A. Pfaller et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)
Michael A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2011)
Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy
Susan J. Howard et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance
Ronen Ben-Ami et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Aneuploidy Drives Genomic Instability in Yeast
Jason M. Sheltzer et al.
SCIENCE (2011)
Importance of Candida-bacterial polymicrobial biofilms in disease
Melphine M. Herriott et al.
TRENDS IN MICROBIOLOGY (2011)
PHARMACOLOGY AND METABOLISM OF ANIDULAFUNGIN, CASPOFUNGIN AND MICAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDOSIS - REVIEW OF THE LITERATURE
G. Kofla et al.
EUROPEAN JOURNAL OF MEDICAL RESEARCH (2011)
Echinocandin-Resistant Candida: Molecular Methods and Phenotypes
David S. Perlin
CURRENT FUNGAL INFECTION REPORTS (2011)
Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species
Guillermo Garcia-Effron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Fungal echinocandin resistance
Louise A. Walker et al.
FUNGAL GENETICS AND BIOLOGY (2010)
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp.
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Breakthrough Invasive Candidiasis in Patients on Micafungin
Christopher D. Pfeiffer et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Comparative Efficacy of Echinocandins and Nonechinocandins for the Treatment of Candida parapsilosis Infections A Meta-analysis
Pramodini B. Kale-Pradhan et al.
PHARMACOTHERAPY (2010)
PKC Signaling Regulates Drug Resistance of the Fungal Pathogen Candida albicans via Circuitry Comprised of Mkc1, Calcineurin, and Hsp90
Shantelle L. LaFayette et al.
PLOS PATHOGENS (2010)
Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints
Guillermo Garcia-Effron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Role for Fks1 in the Intrinsic Echinocandin Resistance of Fusarium solani as Evidenced by Hybrid Expression in Saccharomyces cerevisiae
Santosh K. Katiyar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint
Guillermo Garcia-Effron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Biofilm Formation and Effect of Caspofungin on Biofilm Structure of Candida Species Bloodstream Isolates
J. A. G. Ferreira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2009)
Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit
M. A. Ghannoum et al.
CLINICAL MICROBIOLOGY AND INFECTION (2009)
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease
Leah E. Cowen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Hsp90 Orchestrates Stress Response Signaling Governing Fungal Drug Resistance
Leah E. Cowen
PLOS PATHOGENS (2009)
Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Sheena D. Singh et al.
PLOS PATHOGENS (2009)
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during Candidemia treatment
John D. Cleary et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies
Guillermo Garcia-Effron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans
Nathan P. Wiederhold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection
George R. Thompson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility
Guillermo Garcia-Effron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Stress, drugs, and evolution: The role of cellular signaling in fungal drug resistance
Leah E. Cowen et al.
EUKARYOTIC CELL (2008)
Functional analysis of Candida albicans GPI-anchored proteins: Roles in cell wall integrity and caspofungin sensitivity
Armel Plaine et al.
FUNGAL GENETICS AND BIOLOGY (2008)
Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy
Nabil Kabbara et al.
HAEMATOLOGICA (2008)
Increasing incidence of Candida parapsilosis candidemia with caspofungin usage
Graeme N. Forrest et al.
JOURNAL OF INFECTION (2008)
Stimulation of chitin synthesis rescues Candida albicans from echinocandins
Louise A. Walker et al.
PLOS PATHOGENS (2008)
Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin
Jason M. Cota et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Emergence of Candida tropicalis resistant to caspofungin
Tim Pasquale et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: Six years of global surveillance
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients
Lillian S. Chou et al.
PHARMACOTHERAPY (2007)
Immune recognition of candida albicans β-glucan by dectin-1
Neil A. R. Gow et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Effects of serum on in vitro susceptibility testing of echinocandins
Zekaver Odabasi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Resistance to echinocandin-class antifungal drugs
David S. Perlin
DRUG RESISTANCE UPDATES (2007)
Serum differentially alters the antifungal properties of echinocandin drugs
Padmaja Paderu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera
Nathan P. Wiederhold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase
Jennifer Nielsen Kahn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans
Carol A. Munro et al.
MOLECULAR MICROBIOLOGY (2007)
Mutation as a stress response and the regulation of evolvability
Rodrigo S. Galhardo et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2007)
Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans
J. C. Bowman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Escape of Candida from caspofungin inhibition at concentrations above the MIC (Paradoxical effect) accomplished by increased cell wall chitin;: Evidence for β-1,6-glucan synthesis inhibition by caspofungin
David A. Stevens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility
Santosh Katiyar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin
CD Miller et al.
PHARMACOTHERAPY (2006)
Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility
K Niimi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis
M Laverdière et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Biofilms and their role in the resistance of pathogenic Candida to antifungal agents
C d'Enfert
CURRENT DRUG TARGETS (2006)
Assessment of the paradoxical effect of caspofungin in therapy of candidiasis
KV Clemons et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies
GN Mattiuzzi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata
F Barchiesi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Hsp90 potentiates the rapid evotution of new traits: Drug resistance in diverse fungi
LE Cowen et al.
SCIENCE (2005)
Paradoxical effect of caspofungin:: Reduced activity against Candida albicans at high drug concentrations
DA Stevens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation
JAH van Burik et al.
CLINICAL INFECTIOUS DISEASES (2004)
Antifungal combinations against Candida albicans biofilms in vitro
SP Bachmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Global distribution and outcomes for Candida species causing invasive candidiasis:: Results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis
AL Colombo et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2003)
Antifungal agents: mechanisms of action
FC Odds et al.
TRENDS IN MICROBIOLOGY (2003)
Caspofungin activity against clinical isolates of fluconazole-resistant Candida
MA Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling
C Reinoso-Martin et al.
EUKARYOTIC CELL (2003)
Comparison of caspofungin and amphotericin B for invasive candidiasis.
J Mora-Duarte et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro
JC Bowman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance
SP Bachmann et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Antifungal susceptibility of Candida biofilms:: Unique efficacy of amphotericin B lipid formulations and echinocandins
DM Kuhn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Discovery of novel antifungal (1,3)-β-D-glucan synthase inhibitors
J Onishi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
